Mukka Proteins approves Rs 11.10 Cr investment for 51% stake

1 min read     Updated on 13 Jun 2026, 04:32 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Mukka Proteins Limited approved a strategic investment of up to Rs 11.10 crore to acquire a 51% stake in Delta Marine Products, a partnership firm involved in manufacturing fish meal and fish oil. The Board approved the capital contribution on June 12, 2026, with the transaction expected to be completed by September 30, 2026. Delta Marine Products reported a turnover of Rs 28.16 crore for FY 2024-25.

powered bylight_fuzz_icon
42813657

*this image is generated using AI for illustrative purposes only.

Mukka Proteins Limited approved a strategic investment to acquire a 51% stake in Delta Marine Products for an amount not exceeding Rs 11.10 crore. The Board of Directors approved the capital contribution in one or more tranches on June 12, 2026, to expand the company's core business of manufacturing fish meal and fish oil.

The investment targets Delta Marine Products, a partnership firm incorporated on August 12, 2023, operating within the same industry. The acquisition is not a related party transaction and will be settled through cash consideration. The transaction is expected to be completed by September 30, 2026.

Financials of the Target Entity

Delta Marine Products reported a turnover of Rs 28.16 crore for FY 2024-25, a significant increase from Rs 3.64 crore in the previous year. However, the firm posted a loss after tax (PAT) of Rs 19.72 lakh for FY 2024-25.

Metric Value
Turnover (FY 2024-25) Rs 28,16,99,338/-
PAT (FY 2024-25) Rs (19,72,919/-)
Turnover (As on March 2024) Rs 3,64,15,650/-
Date of Incorporation 12-08-2023

Strategic Rationale

The proposed investment aligns with Mukka Proteins 's strategic plans to focus on capacity expansion and optimization of operational processes. The company stated that this move would lead to improved production efficiency and a broader market reach. The target entity operates exclusively in India, manufacturing fish meal and fish oil.

Historical Stock Returns for Mukka Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
+8.36%+3.87%-5.43%-6.25%-28.61%-46.01%

How does Mukka Proteins plan to address the target entity's recent profitability issues post-acquisition?

What specific operational synergies are expected to improve production efficiency following this integration?

Will this acquisition trigger further consolidation within the domestic fish meal and fish oil industry?

Mukka Proteins FY26 PAT Rises 18.7% to INR 57.1 Cr

2 min read     Updated on 23 May 2026, 04:23 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Mukka Proteins Limited reported a 18.7% increase in FY26 PAT to INR 57.1 crore, driven by a 44% rise in revenue to INR 1,449.5 crore. Q4 PAT grew 52.6% to INR 21.4 crore. The board approved raising INR 75 crore through NCD issuances and authorized investments in a new Sri Lankan subsidiary and a domestic joint venture for waste management.

powered bylight_fuzz_icon
40143133

*this image is generated using AI for illustrative purposes only.

Mukka Proteins Limited has announced its audited financial results for the quarter and year ended March 31, 2026, reporting strong growth across key metrics. The company achieved a revenue of INR 1,449.5 crore for the full year, a significant increase of 44.0% year-on-year. Profit after tax (PAT) for FY26 stood at INR 57.1 crore, up 18.7% from the previous year, while EBITDA grew 30.9% to INR 145.3 crore. The board approved the financial results at its meeting on May 15, 2026.

Consolidated Performance

Mukka Proteins delivered robust consolidated results for the fourth quarter. Q4 revenue reached INR 380.6 crore, while EBITDA surged 48.0% to INR 49.2 crore. The EBITDA margin expanded by 421 basis points to 12.9%. Q4 PAT rose 52.6% to INR 21.4 crore, with a PAT margin of 5.6%. The company attributed the performance to strong demand, improved pricing, and operational efficiencies.

Metric Q4 FY26 Q4 FY25 YoY %
Revenue from operations INR 380.6 crore INR 381.6 crore -0.3%
EBITDA INR 49.2 crore INR 33.2 crore 48.0%
EBITDA Margin 12.9% 8.7% 421bps
PAT INR 21.4 crore INR 14.0 crore 52.6%
PAT Margin 5.6% 3.7% 194bps

Fund Raising and Strategic Investments

The board approved raising funds by issuing secured, rated, listed, redeemable non-convertible debentures (NCDs) worth INR 25 crore on a private placement basis via the Electronic Bidding Platform (EBP). Additionally, the board approved raising up to INR 50 crore through NCDs in one or more tranches via EBP or non-EBP. The first tranche of INR 25 crore carries a coupon rate of 12.00% per annum and a tenor of 15 months.

In strategic expansion moves, the board approved incorporating an overseas entity in Sri Lanka, "Lanka Bio Proteins Private Limited", with an investment of up to INR 2.50 crore for a 49% stake. The company also approved an investment of INR 2.55 lakh for a 51% profit-sharing stake in a proposed partnership firm, "MPL FC HRC JV", focused on the treatment and disposal of animal waste.

Strategic Expansion and Sustainability

The company is advancing its sustainable sourcing initiatives through the MarinTrust Improver Programme. To bolster capacity, Mukka Proteins is establishing a new facility in the Aljoubah Industrial Area in Oman, spread over 21,249 sq. mt. The company also secured a contract from BBMP/BSWML for integrated animal waste management in Bengaluru.

Historical Stock Returns for Mukka Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
+8.36%+3.87%-5.43%-6.25%-28.61%-46.01%

How will Mukka Proteins' new Oman facility impact its export revenue mix and overall capacity utilization in FY27?

Could the 49% stake in Lanka Bio Proteins signal further Southeast Asian or South Asian market expansion beyond Sri Lanka?

With NCDs carrying a 12% coupon rate, how might rising debt servicing costs affect PAT margins if EBITDA growth moderates in coming quarters?

More News on Mukka Proteins

1 Year Returns:-28.61%